Roche cuts $1bn deal on cancer therapy with Immatics

14-11-2013 PMLiVEComments (0)

Biotechnologyimmatics biotechnologiesRoche

The most advanced project among those licensed to Roche is gastric cancer treatment IMA942, which Immatics said is ready for phase I trials. The company's lead in-house project is IMA901 for renal cell carcinoma, which has reached phase III development ...

Read more on PMLiVE

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top